+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Proteome Sciences Plc (PRM) - Product Pipeline Analysis, 2021 Update

  • PDF Icon

    Company Profile

  • 45 Pages
  • December 2021
  • GlobalData
  • ID: 5519753
Proteome Sciences Plc (Proteome Sciences) is a life sciences company that delivers content for personalized medicine through biomarkers, reagents and services. Its proteomics services include drug development, biomarker discovery, quality management and provision of data insights. The company detects and characterizes deferentially expressed proteins using its proprietary technologies in biological samples for prognostic, diagnostic and therapeutic applications. The company offers its services to pharmaceutical and biotechnology companies and academic research institution. It has a research facility in Frankfurt, Germany and operates in the US, Germany and the UK. Proteome Sciences is headquartered in London, England, the UK.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:


  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company Proteome Sciences Plc
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:


  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
  • To formulate effective Research & Development strategies
  • Develop market-entry and market expansion strategies
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Note: Some sections may be missing if data is unavailable for the company

Table of Contents

  • Proteome Sciences Plc Company Overview
  • Proteome Sciences Plc Company Snapshot
  • Proteome Sciences Plc Pipeline Products and Ongoing Clinical Trials Overview
  • Proteome Sciences Plc - Pipeline Analysis Overview
  • Business Description
  • Proteome Sciences Plc - Key Facts
  • Proteome Sciences Plc - Major Products and Services
  • Proteome Sciences Plc Pipeline Products by Development Stage
  • Proteome Sciences Plc Pipeline Products Overview
  • 10 Protein MCI/AD Panel
  • 10 Protein MCI/AD Panel Product Overview
  • Alzheimer’s CSF 3-Plex Assay
  • Alzheimer’s CSF 3-Plex Assay Product Overview
  • Biomarker Assay - Amyotrophic Lateral Sclerosis
  • Biomarker Assay - Amyotrophic Lateral Sclerosis Product Overview
  • Biomarker Assay - Liver Cancer
  • Biomarker Assay - Liver Cancer Product Overview
  • Biomarker Assay - Renal Carcinoma
  • Biomarker Assay - Renal Carcinoma Product Overview
  • Biomarker Panel - Breast Cancer
  • Biomarker Panel - Breast Cancer Product Overview
  • Biomarker Panel - Esophageal Cancer
  • Biomarker Panel - Esophageal Cancer Product Overview
  • Biomarker Panel - Lung Cancer
  • Biomarker Panel - Lung Cancer Product Overview
  • Biomarker Test - Acute Liver Failure
  • Biomarker Test - Acute Liver Failure Product Overview
  • Biomarker Test - Arterial Thrombosis
  • Biomarker Test - Arterial Thrombosis Product Overview
  • Brain Damage Assay - Plasma
  • Brain Damage Assay - Plasma Product Overview
  • Brain Damage CSF 5-Plex Assay
  • Brain Damage CSF 5-Plex Assay Product Overview
  • Brain Damage CSF 7-Plex Assay
  • Brain Damage CSF 7-Plex Assay Product Overview
  • Diagnostic Assay - Alzheimer's Disease (CSF)
  • Diagnostic Assay - Alzheimer's Disease (CSF) Product Overview
  • SysQuant Global Phosphorylation Assay - Biopsy Tissue
  • SysQuant Global Phosphorylation Assay - Biopsy Tissue Product Overview
  • Proteome Sciences Plc - Key Competitors
  • Proteome Sciences Plc - Key Employees
  • Proteome Sciences Plc - Key Employee Biographies
  • Proteome Sciences Plc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Recent Developments
  • Proteome Sciences Plc, Recent Developments
May 19, 2021: Proteome Sciences announces issuance of key TMT patent and introduction of 18plex TMTpro services
Oct 31, 2019: Proteome Sciences: Trading update and announcement of Board Changes
Jan 23, 2019: Proteome Sciences: Year end trading update
Nov 06, 2018: Proteome Sciences: Trading update confirmation of preferred provider status
Jul 24, 2018: Proteome Sciences: Interim results for the six months ended 30 June 2018
Apr 24, 2018: Proteome Sciences: Preliminary results for the year ended 31 December 2017
Apr 24, 2018: Proteome Sciences Appoints Richard Dennis As Board Director
Oct 18, 2017: Proteome Sciences: GCLP Accreditation and Trading Update
Aug 01, 2017: Proteome Sciences: Directorate changes
Jul 25, 2017: Proteome Sciences: Interim Results for the Six Months Ended 30 June 2017
Appendix
  • Methodology
  • About The Publisher
  • Contact The Publisher
  • Disclaimer

List of Tables
  • Proteome Sciences Plc Pipeline Products and Ongoing Clinical Trials Overview
  • Proteome Sciences Plc Pipeline Products by Equipment Type
  • Proteome Sciences Plc Pipeline Products by Indication
  • Proteome Sciences Plc, Key Facts
  • Proteome Sciences Plc, Major Products and Services
  • Proteome Sciences Plc Number of Pipeline Products by Development Stage
  • Proteome Sciences Plc Pipeline Products Summary by Development Stage
  • 10 Protein MCI/AD Panel - Product Status
  • 10 Protein MCI/AD Panel - Product Description
  • Alzheimer’s CSF 3-Plex Assay - Product Status
  • Alzheimer’s CSF 3-Plex Assay - Product Description
  • Biomarker Assay - Amyotrophic Lateral Sclerosis - Product Status
  • Biomarker Assay - Amyotrophic Lateral Sclerosis - Product Description
  • Biomarker Assay - Liver Cancer - Product Status
  • Biomarker Assay - Liver Cancer - Product Description
  • Biomarker Assay - Renal Carcinoma - Product Status
  • Biomarker Assay - Renal Carcinoma - Product Description
  • Biomarker Panel - Breast Cancer - Product Status
  • Biomarker Panel - Breast Cancer - Product Description
  • Biomarker Panel - Esophageal Cancer - Product Status
  • Biomarker Panel - Esophageal Cancer - Product Description
  • Biomarker Panel - Lung Cancer - Product Status
  • Biomarker Panel - Lung Cancer - Product Description
  • Biomarker Test - Acute Liver Failure - Product Status
  • Biomarker Test - Acute Liver Failure - Product Description
  • Biomarker Test - Arterial Thrombosis - Product Status
  • Biomarker Test - Arterial Thrombosis - Product Description
  • Brain Damage Assay - Plasma - Product Status
  • Brain Damage Assay - Plasma - Product Description
  • Brain Damage CSF 5-Plex Assay - Product Status
  • Brain Damage CSF 5-Plex Assay - Product Description
  • Brain Damage CSF 7-Plex Assay - Product Status
  • Brain Damage CSF 7-Plex Assay - Product Description
  • Diagnostic Assay - Alzheimer's Disease (CSF) - Product Status
  • Diagnostic Assay - Alzheimer's Disease (CSF) - Product Description
  • SysQuant Global Phosphorylation Assay - Biopsy Tissue - Product Status
  • SysQuant Global Phosphorylation Assay - Biopsy Tissue - Product Description
  • Proteome Sciences Plc, Key Employees
  • Proteome Sciences Plc, Key Employee Biographies
  • Proteome Sciences Plc, Other Locations
  • Proteome Sciences Plc, Subsidiaries
  • Glossary

List of Figures
  • Proteome Sciences Plc Pipeline Products by Equipment Type
  • Proteome Sciences Plc Pipeline Products by Development Stage

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • BioXcel Therapeutics Inc
  • Microsaic Systems plc
  • Aushon BioSystems Inc
  • Eurofins Selcia Limited
  • Stemina Biomarker Discovery Inc